Notch3 Protein is a protein involved in key cellular signaling pathways relevant to neurodegenerative diseases. This page provides comprehensive information about its structure, normal biological function, and role in disease pathogenesis.
Notch3 Protein participates in critical cellular processes that, when dysregulated, contribute to neurodegeneration. Understanding this protein's function is essential for developing therapeutic interventions for Alzheimer's disease, Parkinson's disease, and related conditions.
| Notch3 Protein | |
|---|---|
| Protein Name | Notch3 |
| Gene | [NOTCH3](/genes/notch3) |
| UniProt ID | Q01953 |
| PDB Structure | 3BDD, 4OPO, 5M2V |
| Molecular Weight | 272 kDa (full length) |
| Subcellular Localization | Cell membrane (vascular smooth muscle cells), pericytes |
| Protein Family | Notch family (type I transmembrane receptor) |
Notch3 shares the overall architecture of other Notch receptors: extracellular domain with EGF-like repeats and LNR domains, transmembrane region, and intracellular domain. The extracellular domain contains 34 EGF-like repeats. Notably, pathogenic NOTCH3 mutations in CADASIL cluster in the EGF-like repeats, particularly affecting cysteine residues. The protein is heavily expressed in vascular smooth muscle cells and pericytes.
Notch3 is primarily expressed in vascular smooth muscle cells and pericytes, where it regulates vascular development, maturation, and homeostasis. It controls smooth muscle cell differentiation, proliferation, and survival. Notch3 signaling is essential for maintaining arterial wall structure and function. It also regulates blood-brain barrier integrity.
NOTCH3 mutations cause CADASIL, the most common inherited cause of stroke and vascular dementia. Over 230 pathogenic mutations lead to abnormal NOTCH3 protein accumulation in small cerebral vessels, forming characteristic granular osmiophilic deposits (GOM). This disrupts vascular smooth muscle cell function, leading to white matter lesions, lacunar infarcts, and cognitive decline. In AD, Notch3 dysfunction may exacerbate cerebrovascular pathology.
No disease-modifying therapy exists for CADASIL. Strategies being explored include: (1) γ-secretase inhibitors to reduce Notch3 cleavage; (2) monoclonal antibodies to block mutant Notch3 accumulation; (3) small molecules to stabilize vascular smooth muscle cell function. Symptomatic treatments include antiplatelet therapy and blood pressure control.